QCM
CYTK icon

Qsemble Capital Management’s Cytokinetics CYTK Stock Holding History

Qsemble Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,810
Closed -$581K – 423
2026
Q1 		$581K Buy
8,810
+250
+3% +$15.9K 0.04% 336
2025
Q4 		$544K Buy
8,560
+2,495
+41% +$155K 0.05% 364
2025
Q3 		$333K Buy
+6,065
New +$250K 0.03% 383
2025
Q2 		– Sell
-7,843
Closed -$315K – 462
2025
Q1 		$315K Buy
7,843
+2,298
+41% +$106K 0.03% 356
2024
Q4 		$261K Buy
+5,545
New +$288K 0.03% 346

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qsemble Capital Management's CYTK Position: Q2 2026 in Review

Qsemble Capital Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 8,810 shares — an estimated $581K sold.

Qsemble Capital Management first reported a position in CYTK in Q4 2024 and held it in 5 quarters. The position peaked at $581K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Qsemble Capital Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 8,810 Cytokinetics shares in Q2 2026, an estimated $581K.
  • Qsemble Capital Management first reported a position in Cytokinetics in Q4 2024 and held it in 5 quarters.
  • Qsemble Capital Management's Cytokinetics position peaked at $581K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Qsemble Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.